Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Pembrolizumab

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.

IMSA101

1st infusion on Cycle 1 Day 2, and then thereafter as per product label.

Immune checkpoint inhibitor

PULSAR

Patrick Widhelm

Jenny P Sanchez

Kat Irenze, RN

Percy Lee, MD

Sarah Chevalier, RN

Andrew Zeng

Jason Ye, MD

Talia Oughourlian

Drew Moghanaki, MD

Elise Catherine Lemp

Devalingam Mahalingam, MB BCh, BAO, PhD

Caitlyn Kwan

Mai Anh Huynh, MD

Jennifer Traber

Greg Vlacich, MD

Adel Zakharia

Alla Ahmed

Nitin Ohri, MD

Megan Tyler

Aryavarta Kumar, MD

Ahmed Gul

Sarah Neufelf

Mona Arbab, MD

Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.

Patients shall be enrolled in 2 treatment arms as follows:

1. 15 patients in the control arm (PULSAR-ICI alone)
2. 30 patients in the experimental arm (PULSAR-ICI + IMSA101)

PULSAR-ICI with or without IMSA101 treatment will be administered to the patients in Cycles 1, 2, and 3, and thereafter only standard of care ICI monotherapy will be administered to all patients. Each treatment cycle will be 28 days in duration for Cycles 1, 2 and 3, then per standard of care monotherapy thereafter based on the product labels of the prescribed ICI.

The study will start with a safety run-in portion at 2 dose levels for the experimental arm, followed by a randomized portion for both treatment arms. The safety run-in shall employ a 3+3 safety run-in component.

All patients will be followed throughout the study for drug tolerability and safety by collecting clinical and laboratory data, including adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria, SAEs, concomitant medications, and vital signs.

All patients will be assessed for anti-tumor efficacy at screening, prior to the end of Cycle 3, and at 8-week intervals thereafter based on radiographic assessments (all outcome measures per RECIST Version 1.1 and iRECIST).

Tumor types and the corresponding treatment combinations to be evaluated will be identified prior to the first patient enrolled.

All patients will continue to receive their assigned treatment throughout the study until the occurrence of disease progression (based on iRECIST), death, or other unacceptable treatment-related toxicity, or until the study is closed by the sponsor.

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Occurrence of treatment-related adverse events and SAEs

Progression-free at 8-week intervals from 6 months to 22 months

Overall response rate, duration of response, progression-free survival

ImmuneSensor Therapeutics Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies	NCT05846659	Oligoprogressiv...	IMSA101 Immune checkpoi... PULSAR	18 Years -	ImmuneSensor Therapeutics Inc.
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies	NCT05846659	Oligoprogressiv...	IMSA101 Immune checkpoi... PULSAR	18 Years -	ImmuneSensor Therapeutics Inc.

Spots Global Cancer Trial Database for oligoprogressive solid tumor malignancies